Francis Yao Selormey: A Figure in Recent Political Turmoil
February 17, 2025 - 13:34
The name Francis Yao Selormey has resurfaced amidst discussions surrounding the declaration of former Minister for Finance, Ken Ofori-Atta, as a wanted fugitive by the Office of the Special Prosecutor. Selormey, who served as the deputy finance minister under former President Jerry Rawlings, is known for his tumultuous time in office and the legal challenges he faced thereafter.
In recent years, Selormey's health has been a topic of concern, particularly as he spent significant time in jail, relying on a pacemaker and an oxygen tank. His experience highlights the often harsh realities faced by public officials embroiled in legal battles and the impact of such situations on their personal well-being.
As the political landscape evolves, Selormey's story serves as a reminder of the complexities surrounding governance and accountability in the country. The ongoing developments in the case against Ofori-Atta may further shape discussions about past administrations and their legacies.
MORE NEWS
June 8, 2026 - 22:27
What history tells us about Marvell's upcoming S&P 500 inclusionMarvell Technology shares have been climbing sharply after the announcement that the company will join the S&P 500 index on June 22. Investors are betting that the move will bring fresh demand from...
June 8, 2026 - 04:51
Is PDD Holdings Inc. (PDD) A Good Stock To Buy Now?A recent discussion on a value investing forum laid out a bullish case for PDD Holdings Inc., the parent company of e-commerce platforms Temu and Pinduoduo. As of late May, shares were trading near...
June 7, 2026 - 03:13
Apple Stock: Buy, Sell, or Hold?Apple`s stock is trading close to an all-time high, and a series of potential catalysts could sustain the upward momentum. The company continues to benefit from strong demand for its latest iPhone...
June 6, 2026 - 22:38
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are MissingEli Lilly is making a serious push into the vaccine business. The pharmaceutical giant announced a trio of acquisitions totaling $3.8 billion, aimed at building a new division focused on infectious...